Insight Molecular Diagnostics Inc. IMDX
Set alert
2.97 USD +0.01 +0.34%
As of Nov 2, 9:30 AM ET
2.97 Day range 2.97
2.42 52-week range 8.51
- YTD
- -60.40%
- 1 year
- -49.92%
- Open
- 2.97
- Prev close
- 2.96
- Mkt cap
- 97.19M
- Vol
- 4.23K
- Avg vol
- 248.24K
- EPS
- -1.52
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.97
- High
- 2.97
3M chart
Signals (10)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 26, 2026 | 1 week ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 16, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 4, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 25, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
Financials — quick view
IMDX Revenue — quarterly 239.00K
IMDX Net income — quarterly -11.26M
IMDX EPS — quarterly -0.31
News
- Oncocyte (NASDAQ:IMDX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Head-To-Head Analysis
- iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch
- iMDx Amends Chronix Merger Agreement, Replacing Ongoing 10% CNI Monitor Royalty With 10% Sale Payment Upon CNI Monitor Sale
- iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
- LUCID CAPITAL MARKETS Initiates Coverage On Insight Molecular with Buy Rating, Announces Price Target of $8
- Transcript: Insight Molecular Q2 2026 Earnings Conference Call
- Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript
- Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform Leveraging Digital PCR Technology For Reliable dd-cfDNA Results In Transplanted Organ Health Monitoring
- Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
- Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript
Your note
Sign in to keep a note on IMDX — it syncs with the Stock Master app.